SEARCH

SEARCH BY CITATION

References

  • Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong L-Y et al. (2008). The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res 14: 82288235.
  • Allhenn D, Boushehri MAS, Lamprecht A (2012). Drug delivery strategies for the treatment of malignant gliomas. Int J Pharm 436: 299310.
  • Ancrile B, Lim K-H, Counter CM (2007). Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 21: 17141719.
  • Antonyak MA, Moscatello DK, Wong AJ (1998). Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J Biol Chem 273: 28172822.
  • Antonyak MA, Kenyon LC, Godwin AK, James DC, Emlet DR, Okamoto I et al. (2002). Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene 21: 50385046.
  • Bachstetter A, Van Eldik L (2010). The p38 MAP kinase family as regulators of proinflammatory cytokine production in degenerative diseases of the CNS. Aging Dis 1: 199211.
  • Bai R-Y, Staedtke V, Riggins GJ (2011). Molecular targeting of glioblastoma: drug discovery and therapies. Trends Mol Med 17: 301312.
  • Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H et al. (2007). The selectivity of protein kinase inhibitors: a further update. Biochem J 408: 297315.
  • Balyasnikova IV, Wainwright DA, Solomaha E, Lee G, Han Y, Thaci B et al. (2012). Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 Receptor α2. J Biol Chem 287: 3021530227.
  • Barcellos-Hoff MH, Newcomb EW, Zagzag D, Narayana A (2009). Therapeutic targets in malignant glioblastoma microenvironment. Semin Radiat Oncol 19: 163170.
  • Becker Y (2006). Molecular immunological approaches to biotherapy of human cancers – a review, hypothesis and implications. Anticancer Res 26: 11131134.
  • Behin A, Hoang-Xuan K, Carpentier AF, Delattre J-Y (2003). Primary brain tumours in adults. Lancet 361: 323331.
  • Beier D, Schulz J, Beier C (2011). Chemoresistance of glioblastoma cancer stem cells – much more complex than expected. Mol Cancer 10: 128.
  • Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W et al. (2001). SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 98: 1368113686.
  • Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM (2003). Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63: 12701279.
  • Bonavia R, Inda MM, Vandenberg S, Cheng S-Y, Nagane M, Hadwiger P et al. (2011). EGFRvIII promotes glioma angiogenesis and growth through the NFkB, interleukin-8 pathway. Oncogene 31: 40544066.
  • Brat DJ, Bellail AC, Van Meir EG (2005). The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol 7: 122133.
  • Bruyere C, Mijatovic T, Lonez C, Spiegl-Kreinecker S, Berger W, Kast R et al. (2011). Temozolomide-induced modification of the CXC chemokine network in experimental gliomas. Int J Oncol 38: 14531464.
  • Campbell RM, Xin X, Xia X, Ye X, Lee P, Schultz RM et al. (2005). Effect of a selective p38-MAPK inhibitor (LY479754) on the tumor microenvironment: implication of macrophage-derived p38α-MAPK in the growth of murine P815 mastocytoma tumors. AACR Meeting Abstracts 2005: 613-c-614.
  • Chen J, Li Y, Yu T-S, McKay RM, Burns DK, Kernie SG et al. (2012). A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488: 522527.
  • Cheng L, Wu Q, Guryanova OA, Huang Z, Huang Q, Rich JN et al. (2011). Elevated invasive potential of glioblastoma stem cells. Biochem Biophys Res Commun 406: 643648.
  • Christie L-A, Acharya MM, Parihar VK, Nguyen A, Martirosian V, Limoli CL (2012). Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy. Clin Cancer Res 18: 19541965.
  • Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA et al. (2011). Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 17: 60836096.
  • Cui J, Han S-Y, Wang C, Su W, Harshyne L, Holgado-Madruga M et al. (2006). c-Jun NH2-terminal kinase 2α2 promotes the tumorigenicity of human glioblastoma cells. Cancer Res 66: 1002410031.
  • Demuth T, Reavie L, Rennert J, Nakada M, Nakada S, Hoelzinger D et al. (2007). MAP-ing glioma invasion: mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival. Mol Cancer Ther 6: 12121222.
  • Diaz L, Messersmith W, Sokoll L, Sinibaldi V, Moore S, Carducci M et al. (2011). TNF-blockade in patients with advanced hormone refractory prostate cancer. Invest New Drugs 29: 192194.
  • de Dios A, Shih C, López de Uralde B, Sánchez C, del Prado M, Martín Cabrejas LM et al. (2005). Design of potent and selective 2-aminobenzimidazole-based p38α MAP kinase inhibitors with excellent in vivo efficacy. J Med Chem 48: 22702273.
  • Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG et al. (2005). A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotech 23: 329336.
  • Filippova N, Yang X, Wang Y, Gillespie GY, Langford C, King PH et al. (2011). The RNA-binding protein HuR promotes glioma growth and treatment resistance. Mol Cancer Res 9: 648659.
  • Fizazi K, De Bono JS, Flechon A, Heidenreich A, Voog E, Davis NB et al. (2012). Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer 48: 8593.
  • Gabrusiewicz K, Ellert-Miklaszewska A, Lipko M, Sielska M, Frankowska M, Kaminska B (2011). Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. Plos ONE 6: e23902.
  • Gallagher TF, Seibel GL, Kassis S, Laydon JT, Blumenthal MJ, Lee JC et al. (1997). Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg Med Chem 5: 4964.
  • Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S et al. (2004). Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64: 70117021.
  • Gessi S, Sacchetto V, Fogli E, Merighi S, Varani K, Baraldi PG et al. (2010). Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptors. Biochem Pharmacol 79: 14831495.
  • Graeber MB, Scheithauer BW, Kreutzberg GW (2002). Microglia in brain tumors. Glia 40: 252259.
  • Griffin BD, Moynagh PN (2006). Persistent interleukin-1β signaling causes long term activation of NFκB in a promoter-specific manner in human glial cells. J Biol Chem 281: 1031610326.
  • Grivennikov SI, Karin M (2010). Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 21: 1119.
  • de Groot JF, Fuller GN, Kumar A, Piao Y, Eterovic K, Ji Y et al. (2010). Tumour invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 12: 233242.
  • Gruenbaum LM, Schwartz R, Woska JJR, DeLeon RP, Peet GW, Warren TC et al. (2009). Inhibition of pro-inflammatory cytokine production by the dual p38/JNK2 inhibitor BIRB796 correlates with the inhibition of p38 signaling. Biochem Pharmacol 77: 422432.
  • Hardee ME, Marciscano AE, Medina-Ramirez CM, Zagzag D, Narayana A, Lonning S et al. (2012). Resistance of glioblastoma initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β (TGFβ). Cancer Res 72: 41194129.
  • He Y, Kamenecka TM, Shin Y, Song X, Jiang R, Noel R et al. (2011). Synthesis and SAR of novel quinazolines as potent and brain-penetrant c-jun N-terminal kinase (JNK) Inhibitors. Bioorg Med Chem Lett 21: 17191723.
  • Hirose Y, Katayama M, Stokoe D, Haas-Kogan DA, Berger MS, Pieper RO (2003). The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol Cell Biol 23: 83068315.
  • Hirose Y, Katayama M, Berger MS, Pieper RO (2004). Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide. J Neurosurg 100: 10601065.
  • Hong T-M, Teng L-J, Shun C-T, Peng M-C, Tsai J-C (2009). Induced interleukin-8 expression in gliomas by tumor-associated macrohages. J Neurooncol 93: 289301.
  • Hsi LC, Kundu S, Palomo J, Xu B, Ficco R, Vogelbaum MA et al. (2011). Silencing IL-13Rα2 promotes glioblastoma cell death via endogenous signaling. Mol Cancer Ther 10: 11491160.
  • Huang Z, Cheng L, Guryanova O, Wu Q, Bao S (2010). Cancer stem cells in glioblastoma -molecular signaling and therapeutic targeting. Protein Cell 1: 638655.
  • de la Iglesia N, Konopka G, Lim K-L, Nutt CL, Bromberg JF, Frank DA et al. (2008a). Deregulation of a STAT3-Interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness. J Neurosci 28: 58705878.
  • de la Iglesia Nr, Konopka G, Puram SV, Chan JA, Bachoo RM, You MJ et al. (2008b). Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev 22: 449462.
  • Inda M, Bonavia R, Mukasa A, Narita Y, Sah D, Vandenberg S et al. (2010). Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 24: 17311745.
  • Ioannidis S, Lamb ML, Wang T, Almeida L, Block MH, Davies AM et al. (2011). Discovery of 5-Chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway. J Med Chem 54: 262276.
  • Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I et al. (2007). A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26: 24352444.
  • Jin X, Yin J, Kim S-H, Sohn Y-W, Beck S, Lim YC et al. (2011). EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction. Cancer Res 71: 71257134.
  • Jin X, Kim S-H, Jeon H-M, Beck S, Sohn Y-W, Yin J et al. (2012). Interferon regulatory factor 7 regulates glioma stem cells via interleukin-6 and Notch signalling. Brain 135: 10551069.
  • Kam AYF, Tse TTM, Kwan DHT, Wong YH (2007). Formyl peptide receptor like 1 differentially requires mitogen-activated protein kinases for the induction of glial fibrillary acidic protein and interleukin-1α in human U87 astrocytoma cells. Cell Signal 19: 21062117.
  • Kim SM, Oh JH, Park SA, Ryu CH, Lim JY, Kim D-S et al. (2010). Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy. Stem Cells 28: 22172228.
  • Kislin K, McDonough W, Eschbacher J, Armstrong B, Berens M (2009). NHERF-1: modulator of glioblastoma cell migration and invasion. Neoplasia 11: 377387.
  • Kohsaka S, Wang L, Yachi K, Mahabir R, Narita T, Itoh T et al. (2012). STAT3 Inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Mol Cancer Ther 11: 12891299.
  • Kostianovsky AM, Maier LM, Anderson RC, Bruce JN, Anderson DE (2008). Astrocytic regulation of human monocytic/microglial activation. J Immunol 181: 54255432.
  • Krona A, Jarnum S, Salford L, Widegren B, Aman P (2005). Oncostatin M signaling in human glioma cell lines. Oncol Rep 13: 807811.
  • Krtolica A, Parrinello S, Lockett S, Desprez P-Y, Campisi J (2001). Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci U S A 98: 1207212077.
  • Kudo M, Jono H, Shinriki S, Yano S, Nakamura H, Makino K et al. (2009). Antitumor effect of humanized anti-interleukin-6 receptor antibody (tocilizumab) on glioma cell proliferation. J Neurosurg 111: 219225.
  • Kyrkanides S, Olschowka J, Williams J, Hansen J, O'Banion M (1999). TNFalpha and IL-1beta mediate intercellular adhesion molecule-1 induction via microglia-astrocyte interaction in CNS radiation injury. J Neuroimmunol 95: 95106.
  • Laberge R-M, Zhou L, Sarantos MR, Rodier F, Freund A, de Keizer PLJ et al. (2012). Glucocorticoids suppress selected components of the senescence-associated secretory phenotype. Aging Cell 11: 569578.
  • Larkin J, Ferguson T, Pickering L, Edmonds K, James M, Thomas K et al. (2010). A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma. Br J Cancer 103: 11491153.
  • Lassman AB, Rossi MR, Razier JR, Abrey LE, Lieberman FS, Grefe CN et al. (2005). Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 11: 78417850.
  • Lee J-J, Kim B, Park M-J, Lee Y-S, Kim Y-N, Lee B et al. (2011). PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiation. Cell Death Differ 18: 666677.
  • Lefranc F, Brotchi J, Kiss R (2005). Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 23: 24112422.
  • Li R, Li G, Deng L, Liu Q, Dai J, Shen J et al. (2010). IL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1. Oncol Rep 23: 15531559.
  • Liu Q, Li G, Li R, Shen J, He Q, Deng L et al. (2010). IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. J Neurooncol 100: 165176.
  • Liu W-T, Lin C-H, Hsiao M, Gean P-W (2011). Minocycline inhibits the growth of glioma by induced autophagy. Autophagy 7: 165175.
  • Lo H-W, Cao X, Zhu H, Ali-Osman F (2008). Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res 14: 60426054.
  • Lu D-Y, Leung Y-M, Cheung C-W, Chen Y-R, Wong K-L (2010). Glial cell line-derived neurotrophic factor induces cell migration and matrix metalloproteinase-13 expression in glioma cells. Biochem Pharmacol 80: 12011209.
  • Lu T, Tian L, Han Y, Vogelbaum M, Stark GR (2007). Dose-dependent cross-talk between the transforming growth factor-β and interleukin-1 signaling pathways. Proc Natl Acad Sci U S A 104: 43654370.
  • Lukiw W (2004). Gene expression profiling in fetal, aged, and Alzheimer hippocampus: a continuum of stress-related signaling. Neurochem Res 29: 12871297.
  • McCulloch CA, Downey GP, El-Gabalawy H (2006). Signalling platforms that modulate the inflammatory response: new targets for drug development. Nat Rev Drug Discov 5: 864876.
  • McFarland BC, Ma J-Y, Langford CP, Gillespie GY, Yu H, Zheng Y et al. (2011). Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther 10: 23842393.
  • Magnus N, Garnier D, Rak J (2010). Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. Blood 116: 815818.
  • Malchinkhuu E, Sato K, Horiuchi Y, Chihir M, Ohwada S, Ishiuchi S et al. (2005). Role of p38 mitogen-activated kinase and c-Jun terminal kinase in migration response to lysophosphatidic acid and sphingosine-1-phosphate in glioma cells. Oncogene 24: 66766688.
  • Mantovani A, Allavena P, Sica A, Balkwill F (2008). Cancer-related inflammation. Nature 454: 436444.
  • Marcus H, Carpenter K, Price S, Hutchinson P (2010). In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines. J Neurooncol 97: 1123.
  • Markovic DS, Vinnakota K, Chirasani S, Synowitz M, Raguet H, Stock K et al. (2009). Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc Natl Acad Sci U S A 106: 1253012535.
  • Markovic DS, Vinnakota K, van Rooijen N, Kiwit J, Synowitz M, Glass R et al. (2011). Minocycline reduces glioma expansion and invasion by attenuating microglial MT1-MMP expression. Brain Behav Immun 25: 624628.
  • Meini A, Sticozzi C, Massai L, Palmi M (2008). A nitric oxide/Ca2+/calmodulin/ERK1/2 mitogen-activated protein kinase pathway is involved in the mitogenic effect of IL-1β in human astrocytoma cells. Br J Pharmacol 153: 17061717.
  • Mesa RA, Yasothan U, Kirkpatrick P (2012). Ruxolitinib. Nat Rev Drug Discov 11: 103104.
  • Michaud-Levesque J, Bousquet-Gagnon N, Béliveau R (2012). Quercetin abrogates IL-6/STAT3 signaling and inhibits glioblastoma cell line growth and migration. Exp Cell Res 318: 925935.
  • Monje M, Toda H, Palmer T (2003). Inflammatory blockade restores adult hippocampal neurogenesis. Science 302: 17601765.
  • Munoz L, Ralay Ranaivo H, Roy SM, Hu W, Craft JM, McNamara LK et al. (2007). A novel p38alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J Neuroinflammation 4: 21.
  • Myung J, Cho B-K, Kim Y-S, Park S-H (2010). Snail and Cox-2 expressions are associated with WHO tumor grade and survival rate of patients with gliomas. Neuropathology 30: 224231.
  • Nabors LB, Suswam E, Huang Y, Yang X, Johnson MJ, King PH (2003). Tumor necrosis factor α induces angiogenic factor up-regulation in malignant glioma cells. Cancer Res 63: 41814187.
  • Nagasawa DT, Chow F, Yew A, Kim W, Cremer N, Yang I (2012). Temozolomide and other potential agents for the treatment of glioblastoma multiforme. Neurosurg Clin N Am 23: 307322.
  • Nikodemova M, Duncan ID, Watters JJ (2006). Minocycline exerts inhibitory effects on multiple mitogen-activated protein kinases and IkappaBalpha degradation in a stimulus-specific manner in microglia. J Neurochem 96: 314323.
  • Nitta RT, Chu AH, Wong AJ (2008). Constitutive activity of JNK2α2 is dependent on a unique mechanism of MAPK activation. J Biol Chem 283: 3493534945.
  • Nogueira L, Ruiz-Ontañon P, Vazquez-Barquero A, Moris F, Fernandez-Luna JL (2011). The NFκB pathway: a therapeutic target in glioblastoma. Oncotarget 2: 646653.
  • Ohba S, Hirose Y, Kawase T, Sano H (2009). Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells. J Neurooncol 95: 307316.
  • Orjalo AV, Bhaumik D, Gengler BK, Scott GK, Campisi J (2009). Cell surface-bound IL-1α is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network. Proc Natl Acad Sci U S A 106: 1703117036.
  • Park C-M, Park M-J, Kwak H-J, Lee H-C, Kim M-S, Lee S-H et al. (2006). Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res 66: 85118519.
  • Park M, Park I, Hur H, Kim M, Lee H, Woo S et al. (2002). Modulation of phorbol ester -induced regulation of matrix metalloproteinases and tissue inhibitors of metalloproteinases by SB203580, a specific inhibitor of p38 mitogen-activated protein kinase. J Neurosurg 97: 112118.
  • Parrinello S, Coppe J-P, Krtolica A, Campisi J (2005). Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J Cell Sci 118: 485496.
  • Pasi F, Facoetti A, Nano R (2010). IL-8 and IL-6 bystander signaling in human glioblastoma cells exposed to gamma radiation. Anticancer Res 30: 27692772.
  • Patel M, Vogelbaum MA, Barnett GH, Jalali R, Ahluwalia MS (2012). Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. Expert Opin Investig Drugs 21: 12471266.
  • Paugh BS, Bryan L, Paugh SW, Wilczynska KM, Alvarez SM, Singh SK et al. (2009). Interleukin-1 regulates the expression of sphingosine kinase 1 in glioblastoma cells. J Biol Chem 284: 34083417.
  • Piette C, Deprez M, Roger T, Noël A, Foidart J-M, Munaut C (2009). The dexamethasone-induced inhibition of proliferation, migration, and invasion in glioma cell lines is antagonized by macrophage migration inhibitory actor (MIF) and can be enhanced by specific MIF inhibitors. J Biol Chem 284: 3248332492.
  • Plantevin Krenitsky V, Nadolny L, Delgado M, Ayala L, Clareen SS, Hilgraf R et al. (2012). Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. Bioorg Med Chem Lett 22: 14331438.
  • Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA et al. (2010). Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115: 31093117.
  • Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum M, Haque S (2002). Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 21: 84048413.
  • Ramanan S, Kooshki M, Zhao W, Hsu F-C, Robbins ME (2008). PPARα ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-κB and AP-1 pathways. Free Radic Biol Med 45: 16951704.
  • Raychaudhuri B, Vogelbaum M (2011). IL-8 is a mediators of NF-kB induced invasion by gliomas. J Neurooncol 101: 227235.
  • Regan J, Breitfelder S, Cirillo P, Gilmore T, Graham AG, Hickey E et al. (2002). Pyrazole urea-based inhibitors of p38 MAP kinase:? from lead compound to clinical candidate. J Med Chem 45: 29943008.
  • Reynes G, Vila V, Martin M, Parada A, Fleitas T, Reganon E et al. (2011). Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma. J Neurooncol 102: 3541.
  • Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre J-Y (2012). Primary brain tumours in adults. Lancet 379: 19841996.
  • Riemenschneider M, Jeuken J, Wesseling P, Reifenberger G (2010). Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 120: 567584.
  • Rodier F, Coppe J, Patil C, Hoeijmakers W, Munoz D, Raza S et al. (2009). Persistant DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 11: 973979.
  • Rolhion C, Penault-Llorca Fdr KJ-L, Lemaire J-J, Jullien C, Labit-Bouvier C et al. (2001). Interleukin-6 overexpression as a marker of malignancy in human gliomas. J Neurosurg 94: 97101.
  • Rong Y, Belozerov VE, Tucker-Burden C, Chen G, Durden DL, Olson JJ et al. (2009). Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/Activator protein-1 transcriptional activity. Cancer Res 69: 25402549.
  • Rossi J-M, Negrier S, James N, Kocak I, Hawkins R, Davis H et al. (2010). A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer 103: 11541162.
  • Saidi A, Hagedorn M, Allain N, Verpelli C, Sala C, Bello L et al. (2009). Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. Int J Cancer 125: 10541064.
  • Sarkar S, Yong V (2009). Inflammatory cytokine modulation of matrix metalloproteinase expression and invasiveness of glioma cells in a 3-dimensional collagen matrix. J Neurooncol 91: 157164.
  • Sasaki A, Tamura M, Hasegawa M, Ishiuchi S, Hirato J, Nakazato Y (1998). Expression of interleukin-1beta mRNA and protein in human gliomas assessed by RT-PCR and immunohistochemistry. J Neuropathol Exp Neurol 57: 653663.
  • Schnegg CI, Kooshki M, Hsu F-C, Sui G, Robbins ME (2012). PPARδ prevents radiation-induced proinflammatory responses in microglia via transrepression of NF-κB and inhibition of the PKCα/MEK1/2/ERK1/2/AP-1 pathway. Free Radic Biol Med 52: 17341743.
  • Senft C, Priester M, Polacin M, Schroder K, Seifert V, Kogel D et al. (2011). Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells. J Neurooncol 101: 393403.
  • Shao C, Folkard M, Prise K (2008). Role of TGF-beta1 and nitric oxide in the bystander response of irradiated glioma cells. Oncogene 27: 434440.
  • Sharma V, Dixit D, Ghosh S, Sen E (2011a). COX-2 regulates the proliferation of glioma stem like cells. Neurochem Int 59: 567571.
  • Sharma V, Dixit D, Koul N, Mehta VS, Sen E (2011b). Ras regulates interleukin-1b-induced HIF-1alpha transcriptional activity in glioblastoma. J Mol Med 89: 123136.
  • Sierra A, Gottfried-Blackmore AC, McEwen BS, Bulloch K (2007). Microglia derived from aging mice exhibit an altered inflammatory profile. Glia 55: 412424.
  • Singh S, Hawkins C, Clarke I, Squire J, Bayani J, Hide T et al. (2004). Identification of human brain tumour initiating cells. Nature 432: 396401.
  • Sliwa M, Markovic D, Gabrusiewicz K, Synowitz M, Glass R, Zawadzka M et al. (2007). The invasion promoting effect of microglia on glioblastoma cells is inhibited by cyclosporin A. Brain 130: 476489.
  • Solinas G, Marchesi F, Garlanda C, Mantovani A, Allavena P (2010). Inflammation-mediated promotion of invasion and metastasis. Cancer Metastasis Rev 29: 243248.
  • Sparkman NL, Johnson RW (2008). Neuroinflammation associated with aging sensitizes the brain to the effects of infection or stress. Neuroimmunomodulation 15: 323330.
  • Sparmann A, Bar-Sagi D (2004). Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6: 447458.
  • Spooren A, Mestdagh P, Rondou P, Kolmus K, Haegeman G, Gerlo S (2011). IL-1β potently stabilizes IL-6 mRNA in human astrocytes. Biochem Pharmacol 81: 10041015.
  • Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987996.
  • Su Y, Li G, Zhang X, Gu J, Zhang C, Tian Z et al. (2008). JSI-124 inhibits glioblastoma multiforme cell proliferation through G2/M cell cycle arrest and apoptosis augmentation. Cancer Biol Ther 7: 12431249.
  • Sun S, Wang Q, Giang A, Cheng C, Soo C, Wang C-Y et al. (2011). Knockdown of CypA inhibits interleukin-8 (IL-8) and IL-8-mediated proliferation and tumor growth of glioblastoma cells through down-regulated NF-κB. J Neurooncol 101: 114.
  • Suswam E, Li Y, Zhang X, Gillespie GY, Li X, Shacka JJ et al. (2008). Tristetraprolin down-regulates interleukin-8 and vascular endothelial growth factor in malignant glioma cells. Cancer Res 68: 674682.
  • Tada M, Diserens A, Desbaillets I, Jaufeerally R, Hamou M, de Tribolet N (1994). Production of interleukin-1 antagonist by human glioblastoma cells in vitro and in vivo. J Neuroimmunol 50: 187194.
  • Tanabe K, Matsushima-Nishiwaki R, Yamaguchi S, Iida H, Dohi S, Kozawa O (2010). Mechanisms of tumor necrosis factor-alpha-induced interleukin-6 synthesis in glioma cells. J Neuroinflammation 7: 16.
  • Tanabe K, Kozawa O, Iida H (2011). Midazolam suppresses interleukin-1beta-induced interleukin-6 release from rat glial cells. J Neuroinflammation 8: 68.
  • Tchirkov A, Rolhion C, Bertrand S, Dore JF, Dubost JJ, Verrelle P (2001). IL-6 gene amplification and expression in human glioblastomas. Br J Cancer 85: 518522.
  • Tchirkov A, Khalil T, Chautard E, Mokhtari K, Veronese L, Irthum B et al. (2007). Interleukin-6 gene amplification and shortened survival in glioblastoma patients. Br J Cancer 96: 474476.
  • The Cancer Genome Atlas Research Network (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 10611068.
  • Tsuiki H, Tnani M, Okamoto I, Kenyon LC, Emlet DR, Holgado-Madruga M et al. (2003). Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors. Cancer Res 63: 250255.
  • Ueda T, Sasaki M, Elia AJ, Chio IIC, Hamada K, Fukunaga R et al. (2010). Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc Natl Acad Sci U S A 107: 1398413990.
  • Vairano M, Graziani G, Tentori L, Tringali G, Navarra P, Russo CD (2004). Primary cultures of microglial cells for testing toxicity of anticancer drugs. Toxicol Lett 148: 9194.
  • Verstovsek S, Manshouri T, Quintás-Cardama A, Harris D, Cortes J, Giles FJ et al. (2008). WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res 14: 788796.
  • Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA et al. (2010). Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363: 11171127.
  • Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. (2012). A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366: 799807.
  • Von Deimling A, Korshunov A, Hartmann C (2011). The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 21: 7487.
  • Wagner EF, Nebreda AR (2009). Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9: 537549.
  • Wakabayashi T, Kambe F, Cao X, Murakami R, Mitsuyama H, Nagaya T et al. (2004). Inhibitory effects of cyclosporin A on calcium mobilization-dependent interleukin-8 expression and invasive potential of human glioblastoma U251MG cells. Oncogene 23: 69246932.
  • Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM et al. (2009). Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 27: 23932404.
  • Wang L, Liu Z, Balivada S, Shrestha T, Bossmann S, Pyle M et al. (2012). Interleukin-1beta and transforming growth factor-beta cooperate to induce neurosphere formation and increase tumorigenicity of adherent LN-229 glioma cells. Stem Cell Res Ther 3: 5.
  • Waugh DJJ, Wilson C (2008). The interleukin-8 pathway in cancer. Clin Cancer Res 14: 67356741.
  • Weissenberger J, Loeffler S, Kappeler A, Kopf M, Lukes A, Afanasieva TA et al. (2004). IL-6 is required for glioma development in a mouse model. Oncogene 23: 33083316.
  • Weissenberger J, Priester M, Bernreuther C, Rakel S, Glatzel M, Seifert V et al. (2010). Dietary curcumin attenuates glioma growth in a syngeneic mouse model by inhibition of the JAK1,2/STAT3 signaling pathway. Clin Cancer Res 16: 57815795.
  • Wynn TA (2003). IL-13 effector functions. Annu Rev Immunol 21: 425456.
  • Xu K, Shu H-KG (2007). EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas. Cancer Res 67: 61216129.
  • Yamanaka R, Tanaka R, Saitoh T, Okoshi S (1994). Cytokine gene expression on glioma cell lines and specimens. J Neurooncol 21: 243247.
  • Yang F, Brown C, Buettner R, Hedvat M, Starr R, Scuto A et al. (2010). Sorafenib induces growth arrest and apoptosis of human glioblastoma cells via dephosphorylation of STAT3. Mol Cancer Ther 9: 953962.
  • Yeung Y, Bryce N, Adams S, Braidy N, Konayagi M, McDonald K et al. (2012). p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and invasiveness of human U251 glioblastoma cells. J Neurooncol 109: 3544.
  • Yoshino Y, Aoyagi M, Tamaki M, Duan L, Morimoto T, Ohno K (2006). Activation of p38 MAPK and/or JNK contributes to increased levels of VEGF secretion in humanmalignant glioma cells. Int J Oncol 29: 981987.
  • Zhang J, Sarkar S, Cua R, Zhou Y, Hader W, Yong VW (2012). A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 axis. Carcinogenesis 33: 312319.